17 completed, 7 recruiting, 5 active not recruiting, 4 terminated. 37 Phase 2, 4 Phase 1, 3 Phase 3.
Follow Multiple System Atrophy: new trials by email Literature Review of Multiple System Atrophy trials Research Report on Multiple System Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France ATH434 - Multiple System Atrophy | Phase 2 | Enrolling by invitation | Alterity Therapeutics | 7 | 2026-10-01 | 2026-10-09 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| Autologous Stem Cell Therapy in Patients With Multiple System Atrophy MSCs, Placebo - MSA - Multiple System Atrophy, MSA | Phase 2 | Not yet recruiting | Biocells Medical | 50 | 2026-09-01 | 2026-03-11 |
| Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy 3-N-butylphthalide - Multiple System Atrophy | Phase 2 / Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 150 | 2026-08-27 | 2026-10-16 |
| An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy TEV-56286 - Multiple System Atrophy | Phase 2 | Recruiting | Teva Branded Pharmaceutical Products R&D LLC | 200 | 2025-09-30 | 2026-10-09 |
| Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. Administration of Carbidopa/levodopa - Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic | Phase 1 / Phase 2 | Recruiting | Julien Bally | 36 | 2025-07-18 | 2026-01-29 |
| A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) Foralumab Nasal - Multiple System Atrophy | Phase 2 | Recruiting | Tiziana Life Sciences LTD | 5 | 2025-05-19 | 2026-06-10 |
| A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy YA-101, Placebo - Multiple System Atrophy | Phase 2 | Active not recruiting | Dasher Neuroscience Inc. | 75 | 2025-03-03 | 2026-08-19 |
| Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy exidavnemab, Placebo Comparator - Parkinson Disease, Multiple System Atrophy | Phase 2 | Completed | BioArctic AB | 38 | 2024-10-24 | 2026-08-21 |
| A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy TEV-56286, Placebo - Multiple System Atrophy | Phase 2 | Active not recruiting | Teva Branded Pharmaceutical Products R&D LLC | 349 | 2024-10-02 | 2026-11-05 |
| The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism Nicotinamide Riboside, Placebo - Progressive Supranuclear Palsy, Multiple System Atrophy | Phase 2 | Recruiting | Haukeland University Hospital | 330 | 2024-03-05 | 2025-01-10 |
| [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD [18F]-MFBG PET CT, [18F]-FE-PE2I PET CT or PET MRI, [123I]-MIBG SPECT CT - Parkinson Disease, Dementia With Lewy Bodies | Phase 2 / Phase 3 | Recruiting | prof. dr. Koen Van Laere | 113 | 2024-01-19 | 2025-02-06 |
| A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy ONO-2808, Placebo - Multiple System Atrophy (MSA) | Phase 2 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 92 | 2023-09-22 | 2026-10-06 |
| A Biomarker Study of ATH434 in Participants With MSA ATH434 - Multiple System Atrophy | Phase 2 | Completed | Alterity Therapeutics | 10 | 2023-05-23 | 2025-04-01 |
| Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA) KM-819, Placebo - Multiple System Atrophy | Phase 2 | Terminated | Kainos Medicine Inc. | 68 | 2023-02-27 | 2024-09-19 |
| A Study of TAK-341 in Treatment of Multiple System Atrophy Placebo, TAK-341 - Multiple System Atrophy | Phase 2 | Completed | Takeda | 158 | 2022-11-16 | 2026-09-24 |
| Study of ATH434 in Participants with Multiple System Atrophy ATH434 dose level 1, ATH434 dose level 2, Placebo - Multiple System Atrophy | Phase 2 | Completed | Alterity Therapeutics | 77 | 2022-07-01 | 2024-12-13 |
| Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy Autologous Mesenchymal Stem Cells, Placebo - Multiple System Atrophy | Phase 2 | Active not recruiting | Mayo Clinic | 71 | 2021-12-15 | 2026-06-12 |
| Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Droxidopa, Placebo Oral Tablet - Parkinson Disease, Multiple System Atrophy | Phase 2 | Withdrawn | Loma Linda University | 2021-12-01 | 2022-03-02 | |
| A Study of Lu AF82422 in Participants With Multiple System Atrophy Lu AF82422, Placebo - Multiple System Atrophy | Phase 2 | Active not recruiting | H. Lundbeck A/S | 64 | 2021-11-16 | 2026-04-13 |
Showing 20 of 37. Sign in to see all of them.
Parkinson Disease (9) · Shy-Drager Syndrome (6) · Hypotension, Orthostatic (4) · Neurodegenerative Diseases (4) · Primary Dysautonomias (4) · Pure Autonomic Failure (4) · Supranuclear Palsy, Progressive (4) · Movement Disorders (3) · Thyroid Dyshormonogenesis 2A (3) · Synucleinopathies (2) · Alzheimer Disease (1) · Autonomic Nervous System Diseases (1) · Corticobasal Degeneration (1) · Dementia (1)
Basal Ganglia Diseases (37) · Brain Diseases (37) · Central Nervous System Diseases (37) · Nervous System Diseases (37) · Autonomic Nervous System Diseases (36) · Synucleinopathies (35) · Movement Disorders (34) · Neurodegenerative Diseases (33) · Primary Dysautonomias (33) · Cardiovascular Diseases (9) · Hypotension (9) · Vascular Diseases (9) · Parkinsonian Disorders (8) · Tauopathies (5) · Cranial Nerve Diseases (4)
Droxidopa (3) · 8-hydroxyquinazolin-4(3H)-one (2) · ATH434 (2) · 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole (1) · 3-n-butylphthalide (1) · AZD3241 (1) · Carbidopa (1) · Exenatide (1) · Fluoxetine (1) · Immunoglobulins, Intravenous (1) · Inosine Monophosphate (1) · Insulin (1) · KM-819 (1) · Levodopa (1) · Lithium Carbonate (1)
Alterity Therapeutics (3) · Teva Branded Pharmaceutical Products R&D LLC (2) · University Hospital, Toulouse (2) · Yonsei University (2) · AstraZeneca (1) · BioArctic AB (1) · Biocells Medical (1) · Dasher Neuroscience Inc. (1) · EmeraMed (1) · Federico II University (1) · H. Lundbeck A/S (1) · Haukeland University Hospital (1) · Julien Bally (1) · Juvantia Pharma Ltd (1) · Kainos Medicine Inc. (1)
United States (20) · France (10) · Italy (8) · Japan (6) · Spain (6) · United Kingdom (5) · Germany (4) · Austria (3) · Israel (3) · Portugal (3) · South Korea (3) · Poland (2) · Australia (1) · Belgium (1) · Canada (1)
Olivier Rascol, MD (2) · Alessandro Filla, MD (1) · Charalampos Tzoulis, MD, PhD (1) · Charlotte Keywood, MD (1) · Chong Sik Lee (1) · David S Goldstein, M.D. (1) · Italo Biaggioni, MD (1) · Jiali Pu, MD (1) · Jose-Alberto Palma, MD, PhD (1) · Khashayar Dashtipour, M.D. Ph.D. (1) · Koen Van Laere (1) · Luis E Okamoto, MD (1)
PMID 23116538, PMID 25498732, PMID 31022213, PMID 33782836, PMID 34657222, PMID 35040506, PMID 40924149, PMID 41269291, PMID 41321006, PMID 42044642
2023 (3), 2025 (2), 2009 (1), 2018 (1), R01HL144568 (1)